OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by Zacks Research

Key Points

• OKYO Pharma has been upgraded to a "hold" rating by Zacks Research, indicating a shift in analysts' outlook on the stock.
• The company's average rating is now classified as a "Moderate Buy" with a consensus price target of $7.00.
• Institutional investors recently increased their positions in OKYO Pharma, with Dauntless Investment Group LLC investing approximately $2.5 million in the first quarter.

Zacks Research upgraded shares of OKYO Pharma (NASDAQ:OKYO - Free Report) to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Separately, Wall Street Zen raised shares of OKYO Pharma to a "hold" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, OKYO Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

OKYO Pharma Stock Up 6.8%

Shares of OKYO Pharma stock traded up $0.14 on Tuesday, hitting $2.12. The company had a trading volume of 44,745 shares, compared to its average volume of 161,098. OKYO Pharma has a twelve month low of $0.90 and a twelve month high of $3.35. The stock has a 50-day moving average of $2.56 and a 200-day moving average of $2.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new position in OKYO Pharma during the 2nd quarter worth approximately $28,000. Dauntless Investment Group LLC acquired a new stake in OKYO Pharma in the 1st quarter valued at $2,526,000. Finally, FNY Investment Advisers LLC bought a new position in OKYO Pharma during the 1st quarter valued at $25,000. Institutional investors own 2.97% of the company's stock.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.